AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

A Prospective Cohort Study of Multimodal Biomarkers and Progression From Mild Cognitive Impairment to Dementia

Recruitingn/aAges 50 Years - anyAllXuanwu Hospital, Beijing
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This prospective, longitudinal observational cohort study will examine clinical, cognitive, blood-based, and neuroimaging features across the cognitive continuum. It will also assess whether these measures can distinguish disease stages and predict progression from mild cognitive impairment (MCI) to dementia. The study will enroll 600 participants. These will include 200 individuals without cognitive impairment, 200 with MCI, and 200 with dementia. The MCI group will comprise participants with Alzheimer disease-related MCI and non-Alzheimer disease-related MCI. The dementia group will be further characterized by clinical subtype (Alzheimer disease-related versus non-Alzheimer disease-related). At baseline, participants will undergo clinical evaluation, neuropsychological assessment, blood collection, and multimodal magnetic resonance imaging. Neuropsychological assessment, blood collec

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: General criteria: 1. Age 50 years or older. 2. Male or female. 3. Able and willing to comply with the study assessments and follow-up procedures. 4. Able to provide written informed consent, or written informed consent is provided by a legally authorized representative when applicable. Dementia cohort: 1. Diagnosis of dementia established by consensus among three senior neurologists with experience in cognitive disorders. 2. Clinical Dementia Rating score of 1 or higher. 3. Availability of a Chinese-speaking caregiver who can provide information about the participant's clinical condition and who lives with or has contact with the participant for at least 4 days per week. Mild cognitive impairment cohort: 1. Diagnosis of mild cognitive impairment established by consensus among three senior neurologists with experience in cognitive disorders. 2. Clinical Dementia Rating score of 0.5. 3. Availability of a Chinese-speaking caregiver who can provide information about the participant's clinical condition and who lives with or has contact with the participant for at least 4 days per week. Cognitively unimpaired cohort: 1. No history of a major neurological or psychiatric disorder. 2. Clinical Dementia Rating score of 0. Exclusion Criteria: 1. An acute neurological disorder, including acute stroke, or another medical or neurological condition that would prevent valid assessment of cognitive status. 2. A severe psychiatric disorder that would interfere with cognitive assessment or study participation. 3. Terminal malignant disease or another severe medical condition that would prevent completion of the study procedures. 4. Severe visual or hearing impairment that would interfere with neuropsychological assessment. 5. Inability or unwillingness to complete the planned 12-month follow-up.
๐Ÿ’Š

What it tests

  • Observational Multimodal Assessment
๐Ÿ“

Where

1 site
Xuanwu Hospital, Capital Medical University
Beijing, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy